Rationalizing Treatment for Gynecological Cancers During the COVID-19 Pandemic: An Indian Experience

Abstract

Purpose The entire world is currently facing a devastating crisis due to growing coronavirus pandemic, which was declared as a public health emergency by the World Health Organization on March 11, 2020. Management of cancer patients at this time is an overwhelming task. This study highlights our experience in the management of patients of gynecological malignancies over a period of 2 months during the COVID-19 pandemic. Methods Patients of confirmed gynecological malignancies who visited our outpatient clinic and those who received radiotherapy/chemotherapy in March and April 2020 were included for analysis. Guidelines issued by the National Institute of Health and Care Excellence, National Health Service, MD Anderson Cancer Centre and those by young oncologists in Italy were followed with minor modifications while managing the logistics and health worker safety. Results A total of 160 patients were treated in our department during this time period. In total, 44.4% of patients on treatment had associated comorbidities that imposed an additional risk. One hundred twenty-three patients continued treatment with their initial plan of radiotherapy or chemotherapy. New patients were prioritized based on the severity of clinical symptoms and whether the expected outcome would significantly affect their survival and quality of life. Patients were monitored for the development of treatment-related toxicities and COVID-19-related symptoms. Conclusions All oncology personnel need to identify the correct balance between risks and benefit and then proceed with further management. Thus, it is essential to cautiously select patients for treatment, minimizing the risk of exposure but adequately addressing the underlying disease.

Truscreen Detection of Cervical Tissues for High-Risk Human Papillomavirus-Infected Women During the COVID-19 Pandemic

“…In gynecologic oncology, the diagnostic and therapeutic paradigms have been shifting to maintain critical diseases or gynecological cancers [4][5][6]. Numerous gynecological groups and societies provided surgical and radiation management recommendations for cervical, endometrial and ovarian cancer in early March 2020 [7,8]. The FRANCOGYN group proposed recommendations that are similar to the standard of care but emphasized radiochemotherapy as the first-line treatment for cervical cancer instead of immediate surgical treatment during the pandemic [7].…”

Effect of COVID-19 Pandemic on Gynecological Cancer Radiation During Complete Nationwide Lockdown: Observations and Reflections From Tertiary Care Institute in India

“…Mumbai was the worst affected city during the COVID 19 pandemic in India (12). In the first phase of the pandemic, also corresponding to nationwide lockdown, the gynaecology radiation oncology unit treated at one-third of its capacity which is similar to the rate reported in cancer hospitals in the west as a result of reorganisation of infrastructural and human resources (13)(14)(15)(16)(17). During this period as seen in our results approximately 25-30% patients decided not to receive further treatment due to fear of infection and challenges posed due to nationwide lockdown reducing patients' ability to travel for 8-week treatment.…”

Contingency planning for cancer care in low- and middle-income countries during the COVID-19 pandemic: a rapid assessment for future disaster resilience

“…In Asia, various approaches were noted. While the Philippine Society of Medical Oncology had published separate consensus recommendations for management of eleven types of cancers during the COVID-19 pandemic [ 16 ], India had a number of guidelines drawn up by different groups for different types of cancers [ 17 – 19 ]. The National Cancer Grid of India meanwhile appears to be finalising a set of official guidelines for cancer management during the COVID-19 outbreak [ 20 ].…”